Showing 8531-8540 of 10813 results for "".
- NPF and Boehringer Unite to Launch First GPP Awareness Dayhttps://practicaldermatology.com/news/NPF-Boehringer-Unite-Launch-First-GPP-Awareness-Day/2475890/Key Takeaways NPF and Boehringer Ingelheim launched a campaign to educate and support individuals with generalized pustular psoriasis.
- Dupilumab Linked to Higher Psoriasis Risk in AD Patientshttps://practicaldermatology.com/news/dupilumab-linked-to-higher-psoriasis-risk-in-ad-patients/2475230/Patients with atopic dermatitis (AD) prescribed dupilumab face a higher risk of developing psoriasis compared to those receiving other systemic agents, according to a large retrospective cohort study in JAMA Dermatology.
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://practicaldermatology.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.
- From ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://practicaldermatology.com/news/new-laser-platforms-expand-options-for-vascular-rosacea/2474325/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of
- FDA Approves Dupilumab for CSU in Adults 12 and Olderhttps://practicaldermatology.com/news/FDA-Approves-Dupilumab-CSU-Adults-12-Older/2474212/The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with histamine-1 (H1) ant
- Researchers Identify Novel IL-17A-Linked Psoriasis Gene and Therapeutic Targethttps://practicaldermatology.com/news/plek-identified-as-novel-il-17a-linked-psoriasis-gene-and-therapeutic-target/2473942/Machine learning and in vivo experimentation have identified
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline